<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><link rel="stylesheet" href="/css/isb.css" /><title>ProteomeXchange Dataset PXD021924</title>
</head><body bgcolor="#f4f6f8" marginwidth="0" marginheight="0">	<table width="100%" height="127" background="/images/topbackground.jpg" style="box-shadow: 0 6px 8px 0 rgba(0,0,0,0.3);">	<tr align="center"><td><a href="http://www.proteomexchange.org/" border="0"><img src="/images/proteomexchange.png"></a></td><td><a href="http://proteomecentral.proteomexchange.org/" border="0"><img src="/images/proteomecentral.png"></a></td></tr>	</table>		<!-- Main content area here --><!-- BEGIN main content -->

	 <link rel='stylesheet' id='style-css'  href='../javascript/css/patchwork.css' type='text/css' media='all' />
         <script type="text/javascript" src="/javascript/js/toggle.js"></script>
      
       <div id="main">
       <a class="linkback" href="http://proteomecentral.proteomexchange.org/cgi/GetDataset"> &lt;&lt;&lt; Full experiment listing </a>
       <div id="dataset-primary" class="site-content">
       <h1 class="dataset-title">PXD021924</h1>
    
	<div class="dataset-content">
	PXD021924 is an <b>original dataset</b> announced via ProteomeXchange.<BR><BR><div class='dataset-secthead'>Dataset Summary</div>
<table class='dataset-summary'><tr><td><b>Title</b></td><td>Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer</td></tr><tr><td><b>Description</b></td><td class='breakwords'>The glucocorticoid receptor (GR) regulates gene expression throughout the human genome in a cell-type-specific manner, governing various aspects of homeostasis. The influence of this transcriptional regulator is seen in multiple pathologies, including cancer. Pharmacological activation of the GR is frequently used to alleviate side-effects caused by therapy for patients with various non-lymphoid solid  (i.e. non-hematologic) cancers; however, prior studies have shown that this treatment might also have anti-proliferative action on cancer cells. Nonetheless, the molecular underpinnings of glucocorticoid action and its direct effectors in non-lymphoid solid cancers remain elusive. Here, we study the molecular mechanisms of glucocorticoid response in non-lymphoid solid cancers models, focusing on lung cancer. Activation of the GR induces reversible cancer cell dormancy in which cells are tolerant to large array of anti-cancer drugs. This state transition is accompanied by induction of growth factor survival signalling (IGF-1R) and acquired vulnerability to inhibitors of this pathway, both in vitro and in vivo. The observed phenotype is dependent on a single GR target gene - CDKN1C, which encodes for a cell cycle inhibitor protein p57. We have discovered an upstream distal enhancer of CDKN1C, which through GR-induced chromatin looping regulates the expression of this key gene, as confirmed in human tumour specimens. Furthermore, we demonstrate that the SWI/SNF complex composition fine-tunes the GR transcriptional activity at the CDKN1C locus, allowing for precise regulation of cell dormancy induction. Collectively, we show that SWI/SNF-facilitated regulation of CDKN1C underlines GR-induced reversible drug-tolerant state in cancer cells. These insights illustrate the importance of GR signalling in non-lymphoid solid cancer biology, particularly in lung cancer, and warrant caution for use of glucocorticoids in treatment of anti-cancer therapy related side-effects.</td></tr><tr><td><b>HostingRepository</b></td><td>PRIDE</td></tr><tr><td><b>AnnounceDate</b></td><td>2021-05-17</td></tr>
                <tr><td><b>AnnouncementXML</b></td><td><a href='GetDataset?ID=PXD021924.0-2&outputMode=XML&test=no' target="_blank">Submission_2021-08-26_04:29:55.001.xml</a></td></tr>
                <tr><td><b>DigitalObjectIdentifier</b></td><td><a href="" target="_blank"></a></td></tr><tr><td><b>ReviewLevel</b></td><td>Peer-reviewed dataset</td></tr><tr><td><b>DatasetOrigin</b></td><td>Original dataset</td></tr><tr><td><b>RepositorySupport</b></td><td>Unsupported dataset by repository</td></tr><tr><td><b>PrimarySubmitter</b></td><td>Liesbeth Hoekman</td></tr><tr><td><b>SpeciesList</b></td><td> scientific name: Homo sapiens (Human);  NCBI TaxID: 9606; </td></tr><tr><td><b>ModificationList</b></td><td>phosphorylated residue; monohydroxylated residue; iodoacetamide derivatized residue; deamidated residue</td></tr><tr><td><b>Instrument</b></td><td>Q Exactive HF-X; Orbitrap Fusion</td></tr></table>
<div class='dataset-secthead'>Dataset History</div>
<table class="dataset-summary">
<tr><th>Revision</th><th>Datetime</th><th>Status</th><th>ChangeLog Entry</th></tr>
<tr><td >0</td><td >2020-10-12 06:55:14</td><td >ID requested</td><td ></td></tr>
<tr><td ><a href="GetDataset?ID=PXD021924-1&test=no">1</a></td><td >2021-05-17 03:07:37</td><td >announced</td><td ></td></tr>
<tr><td class="dataset-currentrev"><a href="GetDataset?ID=PXD021924-2&test=no"><span class='current'>&#9205;</span> 2</a></td><td class="dataset-currentrev">2021-08-26 04:29:56</td><td class="dataset-currentrev">announced</td><td class="dataset-currentrev">2021-08-26: Updated publication reference for PubMed record(s): 34272384.</td></tr>
</table>
<div class='dataset-secthead'>Publication List </div>
<table class='dataset-summary'>
<tr><td>Prekovic S, Schuurman K, Mayayo-Peralta I, Manjón AG, Buijs M, Yavuz S, Wellenstein MD, Barrera A, Monkhorst K, Huber A, Morris B, Lieftink C, Chalkiadakis T, Alkan F, Silva J, Győrffy B, Hoekman L, van den Broek B, Teunissen H, Debets DO, Severson T, Jonkers J, Reddy T, de Visser KE, Faller W, Beijersbergen R, Altelaar M, de Wit E, Medema R, Zwart W, Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer. Nat Commun, 12(1):4360(2021) [<a href="https://www.ncbi.nlm.nih.gov/pubmed?term=34272384" target="_blank">pubmed</a>]</td></tr></table>
<div class='dataset-secthead'>Keyword List </div>
<table class='dataset-summary'>
<tr><td>submitter keyword: Human, LC-MSMS, RIME, LFQ, lung cancer, glucocorticoid receptor, CDKN1C, protein p57, proteome, Phosphoproteome</td></tr></table>
<div class='dataset-secthead'>Contact List </div>
<table class='dataset-summary'>
<tr><th colspan='2'>Maarten Altelaar</th></tr>
<tr><td>contact affiliation</td><td>Mass spectrometry/Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands</td></tr><tr><td>contact email</td><td>m.altelaar@nki.nl</td></tr><tr><td>lab head</td><td></td></tr><tr><th colspan='2'>Liesbeth Hoekman</th></tr>
<tr><td>contact affiliation</td><td>The Netherlands Cancer Institute, Amsterdam, The Netherlands.</td></tr><tr><td>contact email</td><td>l.hoekman@nki.nl</td></tr><tr><td>dataset submitter</td><td></td></tr></table>
<div class='dataset-secthead'>Full Dataset Link List </div>
<table class='dataset-summary'>
<tr><td><a href=ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD021924 target="_blank">Dataset FTP location</a></td></tr><tr><td><a href=http://www.ebi.ac.uk/pride/archive/projects/PXD021924 target="_blank">PRIDE project URI</a></td></tr></table>

		 <div class='dataset-secthead'>Repository Record List </div>
                 <div id="less" onclick='toggle("less","more","repositoryRecordList")' title='Expand Record List'>[ + ]</div>
		 <div id="more" onclick='toggle("more","less","repositoryRecordList")' title='Hide Record List' style='display: none'>[ - ]</div>
		 <ul id="repositoryRecordList" style='display: none'>
        <li>PRIDE<ol><li><a href="http://www.ebi.ac.uk/pride/archive/projects/PXD021924" target="_blank">PXD021924</a><ol><li>Label: PRIDE project</li><li>Name: Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer</li></ol></li></li></ul>

      
	 </div><!-- #content -->
	 </div><!-- #primary .site-content -->
	 </div><!-- #main -->
      <!-- END main content -->	<!-- Begin Footer -->	<br clear="all">	<div class="footer">	<table width="100%"><tr>	<td style="vertical-align:top; text-align:left; padding: 10px;">If you have a question or comment about ProteomeXchange, please <a href="http://www.proteomexchange.org/contact">contact us</a>!<BR>	<a href="http://www.proteomexchange.org/subscribe/index.html"><img width="70" height="20" src="/images/subscribe_button-small.jpg"><font size="+1" color="#aa0000"> to receive all new ProteomeXchange dataset release announcements!</font></a>	</td>	<td style="text-align:right; padding: 10px;">	<a class="logolink" target="_blank" href="http://www.ebi.ac.uk/"><img src="/images/ebi_footer_logo.png"></a>&nbsp;&nbsp;&nbsp;&nbsp;	<a class="logolink" target="_blank" href="http://www.isbscience.org/"><img src="/images/isb.jpg"></a>&nbsp;&nbsp;&nbsp;&nbsp;	<a class="logolink" target="_blank" href="http://ec.europa.eu/research/fp7/index_en.cfm"><img src="/images/capacities.png"></a>	</td></tr></table>	</div>				</body></html>